Browsing by Author de la Mata, Manuel

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
PreviewTitleAuthor(s)Issue Date
AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.González-Rubio, Sandra; Linares, Clara I; Aguilar-Melero, Patricia; Rodríguez-Perálvarez, Manuel; Montero-Álvarez, José L; de la Mata, Manuel; Ferrín, Gustavo4-Aug-2016
Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease.Del Río-Moreno, Mercedes; Alors-Pérez, Emilia; González-Rubio, Sandra; Ferrín, Gustavo; Reyes, Oscar; Rodríguez-Perálvarez, Manuel; Sánchez-Frías, Marina E; Sánchez-Sánchez, Rafael; Ventura, Sebastián; López-Miranda, José; Kineman, Rhonda D; de la Mata, Manuel; Castaño, Justo P; Gahete, Manuel D; Luque, Raúl M2019
Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.Gómez-Bravo, Miguel; Prieto Castillo, Martín; Navasa, Miquel; Sánchez-Antolín, Gloria; Lladó, Laura; Otero, Alejandra; Serrano, Trinidad; Jiménez Romero, Carlos; García González, Miguel; Valdivieso, Andrés; González-Diéguez, María Luisa; de la Mata, Manuel; Pons, José A; Salcedo, Magdalena; Rodrigo, Juan M; Cuervas-Mons, Valentín; González Rodríguez, Antonio; Caralt, Mireia; Pardo, Fernando; Varo Pérez, Evaristo; Crespo, Gonzalo; Rubin, Ángel; Guilera, Magda; Aldea, Anna; Santoyo, Julio2022
Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation.Rodríguez-Perálvarez, Manuel; Amado, Victor; de la Mata, Manuel2019
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.Pinyol, Roser; Montal, Robert; Bassaganyas, Laia; Sia, Daniela; Takayama, Tadatoshi; Chau, Gar-Yang; Mazzaferro, Vincenzo; Roayaie, Sasan; Lee, Han Chu; Kokudo, Norihiro; Zhang, Zhongyang; Torrecilla, Sara; Moeini, Agrin; Rodriguez-Carunchio, Leonardo; Gane, Edward; Verslype, Chris; Croitoru, Adina Emilia; Cillo, Umberto; de la Mata, Manuel; Lupo, Luigi; Strasser, Simone; Park, Joong-Won; Camps, Jordi; Solé, Manel; Thung, Swan N; Villanueva, Augusto; Pena, Carol; Meinhardt, Gerold; Bruix, Jordi; Llovet, Josep M14-Aug-2018
mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.Guerrero, Marta; Ferrín, Gustavo; Rodríguez-Perálvarez, Manuel; González-Rubio, Sandra; Sánchez-Frías, Marina; Amado, Víctor; Pozo, Juan C; Poyato, Antonio; Ciria, Rubén; Ayllón, María D; Barrera, Pilar; Montero, José L; de la Mata, Manuel15-Jan-2019
Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients.Aguiar, Diego; Martínez-Urbistondo, Diego; Baroja-Mazo, Alberto; de la Mata, Manuel; Rodríguez-Perálvarez, Manuel; Rubín, Angel; Puchades, Lorena; Serrano, Trinidad; Montero, Jessica; Cuadrado, Antonio; Casafont, Fernando; Salcedo, Magdalena; Rincón, Diego; Pons, Jose A; Herrero, Jose I2-May-2017
Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation.Ayllón, María Dolores; Ciria, Rubén; Cruz-Ramírez, Manuel; Pérez-Ortiz, María; Gómez, Irene; Valente, Roberto; O'Grady, John; de la Mata, Manuel; Hervás-Martínez, César; Heaton, Nigel D; Briceño, Javier2018